全球蓝眼病疫苗市场规模（依产品类型、应用、区域范围、预测）

蓝眼症疫苗市场规模及预测

蓝眼疫苗市场规模在 2024 年价值 32 亿美元，预计到 2032 年将达到 62.4 亿美元，预测期内（2026-2032 年）的复合年增长率为 3.93%。

该报告对市场动态进行了深入分析，包括关键细分市场、趋势、驱动因素、限制因素、竞争格局以及在市场中发挥关键作用的因素。

定义全球蓝眼病疫苗市场

蓝眼症是一种病毒性疾病，常见于哺乳猪隻和生长猪。蓝眼症由猪红斑病毒引起。此病通常表现为脑炎、肺炎和呼吸道疾病。蓝眼症也会导致成年猪的繁殖障碍和角膜混浊（一种以角膜瘢痕为特征的眼部疾病）。

临床症状和溃疡是诱发因素之一，但它们可能与其他疾病混淆。目前已开发出几种检测RNA、抗体和抗原成分的机制。据报道，有两种针对蓝眼病病毒的疫苗：一种是用于马、骡和驴的有机疫苗（单价和多效价），另一种是无效的单价血清型4疫苗，该疫苗已在市场上销售，但目前尚未上市。含有次单元的新型疫苗也正在测试中。

蓝眼疫苗可帮助患有各种感染疾病的患者，改善患者照护并提高整体业务效率。医院感染疾病的高发病率和发病率导致越来越多的患者涌入私人诊所和医院，这是由于人们对住宅、商业/工业场所/医疗机构的卫生状况和感染疾病传播的担忧日益加剧。综合考虑这些因素，蓝眼科疾病疫苗的需求预计将很快上升。

过去二十年，蓝眼病疫苗市场规模快速成长，但同时，企业结构和员工行为模式也发生了变化，带来了许多挑战。全球蓝眼病疫苗市场正在经历重大变革，製造商必须不断创新才能维持其工作结构。

蓝眼症疫苗全球市场概况

蓝眼症在中部和中西部地区流行，这些地区是热带和亚热带地区的主要生猪产区。市场机会包括新兴市场意识的提升以及兽医护理支出的增加。这些因素预计很快就会推动蓝眼病疫苗的需求。

预计刺激全球蓝眼病疫苗市场的主要因素包括：多种预防性疫苗研发计画投资的增加，以及监管机构发布的与物种健康相关的蓝眼治疗指南。技术先进的医疗基础设施建设，以及与国际大学和知名供应商合作的研发计划，将为全球蓝眼病疫苗市场带来丰厚的成长机会。

然而，全球蓝眼疫苗市场面临挑战，因为全球有很大一部分人口，尤其是在新兴经济体，尚未接种此类疫苗。全球范围内的移民和其他流动，包括不断增长的外国旅客数量以及人口增长，催生了大规模生产此类疫苗的需求。然而，该领域设施运作和维护的高成本可能会阻碍市场成长。此外，合格专业人员的短缺也是市场成长的挑战。

预计过多的非结构化数据将减缓经济成长。电子元件互连日益复杂、全球大宗商品价格下跌以及近期新冠疫情的爆发，为蓝眼疫苗市场带来了许多挑战。然而，资料中心对网路和储存设备的需求不断增长，智慧医疗基础设施、机器人技术以及医疗应用中基于感测器的设备的需求不断增长，预计将在预测期内为蓝眼病疫苗市场带来重大机会。

目录

第一章蓝眼病疫苗全球市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章蓝眼症疫苗全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球蓝眼病疫苗市场（依产品类型）

• 概述
• 活病毒疫苗
• 灭活疫苗

6. 全球蓝眼病疫苗市场（依应用）

• 概述
• 小猪
• 成年猪

7. 全球蓝眼病疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

8. 全球蓝眼疫苗市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第九章 公司简介

• CAHIC
• Merial
• MSD Animal Health
• Chopper Biology
• Ceva
• ChengDu Tecbond
• Veterinary
• Ringpu Biology
• Qilu Animal
• DHN

第十章 附录

• 相关调查

Blue Eye Disease Vaccines Market Size And Forecast

Blue Eye Disease Vaccines Market size is valued at USD 3.2 Billion in 2024 and is projected to reach USD 6.24 Billion by 2032, growing at a CAGR of 3.93% during the forecast period 2026-2032.

The Blue Eye Disease is endemic in the central and west-central regions, which are the major swine-producing areas in tropical and subtropical areas, As a result of this, the potential for the growth of Blue Eye Disease vaccines in these endemic areas are higher, leading to the growth of the market. The Global Blue Eye Disease Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Blue Eye Disease Vaccines Market Definition

Blue eye disease is a viral disease that occurs in nursing or growing pigs. Blue eye disease is caused by porcine rubulavirus. The disease is commonly identified by encephalitis, pneumonia, and respiratory diseases. Blue eye diseases are also connected to reproductive failure in adult pigs as well as corneal opacity, (eye disorder characterized by scarring of the cornea).

Although clinical symptoms and ulcers are a factor, they can be confused with other diseases. Several mechanisms have been developed to detect components of RNA, antibodies, and antigens. Two types of vaccines have been described with the Blue Eye Disease virus. Organic vaccines (monovalent and polyvalent) for use in horses, mules, and donkeys, are now available, as well as an ineffective, monovalent, serotype 4 vaccine, commercially available but no longer available. New vaccines, including subunits, have been tested.

Blue Eye Disease Vaccines aid patients suffering from different infections to improve overall operational efficiency as well as patient care. The high prevalence and incidence rates of hospital-acquired diseases increased focus on hygiene, and rising concerns over the spread of infectious diseases in both residential and commercial/industrial spaces/healthcare units, have led to an increase in patient flow to private clinics and hospitals. These factors, collectively, are projected to increase the demand for Blue Eye Disease Vaccines soon.

Over the past two decades, the Blue Eye Disease Vaccines Market has grown at an enormous scale, and over time it has brought many challenges with the change in the structure of the company and the way employees behave. The global Blue Eye Disease Vaccines Market is undergoing significant changes, as the manufacturers need to evolve in an attempt to keep the structure of their work.

Global Blue Eye Disease Vaccines Market Overview

The Blue Eye Disease is endemic in the central and west-central regions, which are the major swine-producing are in tropical and subtropical areas, As a result of this, the potential for the growth of Blue Eye Disease vaccines in these endemic areas are higher, leading to the growth of the market. Opportunities in the market include increasing awareness and a rise in expenditure on veterinary care in developing regions. These factors, collectively, are projected to increase the demand for Blue Eye Disease Vaccines shortly.

Increasing investment in R&D programs for the development of several preventive vaccines and guidelines provided by regulatory bodies associated with species health for Blue Eye Disease treatment are the major factors expected to stimulate the global Blue Eye Disease Vaccines Market. Developing technologically advanced healthcare infrastructure and ongoing research projects in association with international universities and prominent vendors for the development of effective vaccines will provide lucrative growth opportunities to the global Blue Eye Disease Vaccines Market.

However, the global Blue Eye Disease Vaccines Market faces challenges as a large percentage of the global population predominantly in developing economies is yet to have its hands on these vaccines. With the increase in the number of foreign travelers, cross migrations and other travels all over the world, including a growing population there is a need for the widespread manufacturing of these vaccines. However, the high costs associated with the operation and maintenance of facilities in the sector will be a hindrance to the growth of the market. In addition, the lack of qualified specialists will challenge the growth of the market.

Excess of unstructured data is expected to slow economic growth. The increasing complexity of interconnecting electronic components, the drop in global commodity prices, and the recent outbreak of COVID-19 have brought up many challenges to the Blue Eye Disease Vaccines Market. Nevertheless, rising demand for networking and storage devices in the data center, demand for smart healthcare infrastructure, robotics in healthcare applications, and sensor-based devices are expected to provide huge opportunities for the Blue Eye Disease Vaccines Market for the forecasted period.

Global Blue Eye Disease Vaccines Market: Segmentation Analysis

The Global Blue Eye Disease Vaccines Market is Segmented on the basis of Product Type, Application, and Geography.

Blue Eye Disease Vaccines Market, By Product Type

• Live Vaccines
• Killed Vaccines

Based on the Product Type, the market is segmented into Live Vaccines and Killed Vaccines. Live Vaccines are those vaccines in which the virus-causing disease is weakened and slowly develops body immunity. Killed Vaccines or Inactivated vaccines have grown viruses, bacteria, or pathogens which are then killed to stop the disease-producing agent.

Blue Eye Disease Vaccines Market, By Application

• Piglets
• Adult Pigs

Based on Application, the market is segmented into Piglets and Adult Pigs. Piglets are the largest contributor to the global market in 2019 in this segment and are very likely to continue the trend in the forecast period.

Blue Eye Disease Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Blue Eye Disease Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region dominated the global market in 2019 followed by Europe and is expected to continue the trend in the forecast period. The Asia Pacific region is expected to grow at a rapid pace in the forecast period owing to rapid urbanization and industrialization with an increased investment towards smart & efficient technology and increased per capita income.

Key Players

The "Global Blue Eye Disease Vaccines Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as CAHIC, Merial, MSD Animal Health, Chopper Biology, Ceva, ChengDu Tecbond, Veterinary, Ringpu Biology, Qilu Animal and DHN.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLUE EYE DISEASE VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLUE EYE DISEASE VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY Product Type

• 5.1 Overview
• 5.2 Live Vaccines
• 5.3 Killed Vaccines

6 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Piglets
• 6.3 Adult Pigs

7 GLOBAL BLUE EYE DISEASE VACCINES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL BLUE EYE DISEASE VACCINES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 CAHIC
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Merial
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 MSD Animal Health
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Chopper Biology
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Ceva
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 ChengDu Tecbond
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Veterinary
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Ringpu Biology
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Qilu Animal
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 DHN
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research